Agilent Technologies (NYSE:A) Announces Earnings Results, Beats Expectations By $0.13 EPS

Agilent Technologies (NYSE:A) issued its quarterly earnings data on Wednesday. The medical research company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.13, FiscalAI reports. The company had revenue of $1.88 billion for the quarter, compared to the consensus estimate of $1.84 billion. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.84%. Agilent Technologies’s revenue for the quarter was up 8.1% on a year-over-year basis. During the same period last year, the firm posted $1.37 EPS. Agilent Technologies updated its Q4 2026 guidance to 1.710-1.740 EPS and its FY 2026 guidance to 6.180-6.210 EPS.

Here are the key takeaways from Agilent Technologies’ conference call:

• Agilent delivered a strong Q3 beat and raised its outlook. Revenue grew 7.3% organically to $1.88 billion, while adjusted EPS excluding tariff refunds rose 14% to $1.56; full-year core growth guidance increased to 5.8%-6.0% and adjusted EPS guidance to $6.12-$6.15.
• Pharma, China, and key applied markets showed broad-based momentum. Pharma grew 12%, China grew 9% versus expectations for flat growth, and chemicals and advanced materials grew 7%, supported by biotech funding, GLP-1 demand, PFAS testing, semiconductor investment, and AI infrastructure spending.
• New products and replacement cycles are supporting demand. LC revenue grew low double digits, book-to-bill remained above one for the 10th consecutive quarter, and early orders for the 9500 ICP-MS, flagship GC systems, and Altura columns exceeded expectations.
• Ignite drove significant operating leverage. Q3 operating margin excluding tariff refunds expanded 210 basis points year over year to 27.2%, with strategic pricing contributing approximately 200 basis points and operational improvements helping offset inflationary and supply-chain pressures.
• The specialty CDMO outlook is strong longer term but faces near-term timing pressure. The business grew nearly 30% in Q3, with about 75% of fiscal 2027 Train C capacity already backed by purchase orders, but Q4 growth is expected to be flat because of regulatory-submission timing and a difficult comparison exceeding 40% growth.

Agilent Technologies Stock Up 1.6%

Shares of Agilent Technologies stock opened at $157.60 on Friday. Agilent Technologies has a one year low of $108.35 and a one year high of $163.75. The company has a market cap of $44.51 billion, a P/E ratio of 31.02, a PEG ratio of 2.74 and a beta of 1.25. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.62 and a current ratio of 2.10. The firm has a fifty day moving average of $139.76 and a two-hundred day moving average of $126.85.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Compound Planning Inc. raised its holdings in Agilent Technologies by 47.8% during the fourth quarter. Compound Planning Inc. now owns 3,705 shares of the medical research company’s stock worth $504,000 after purchasing an additional 1,199 shares in the last quarter. Invesco Ltd. boosted its holdings in Agilent Technologies by 32.0% in the 4th quarter. Invesco Ltd. now owns 2,590,715 shares of the medical research company’s stock valued at $352,519,000 after purchasing an additional 627,804 shares in the last quarter. Corient Private Wealth LLC boosted its holdings in Agilent Technologies by 53.7% in the 4th quarter. Corient Private Wealth LLC now owns 284,303 shares of the medical research company’s stock valued at $38,685,000 after purchasing an additional 99,385 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its stake in shares of Agilent Technologies by 1.9% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 60,542 shares of the medical research company’s stock worth $8,238,000 after buying an additional 1,131 shares in the last quarter. Finally, Vident Advisory LLC lifted its holdings in shares of Agilent Technologies by 4.7% in the 4th quarter. Vident Advisory LLC now owns 17,052 shares of the medical research company’s stock valued at $2,320,000 after buying an additional 765 shares during the period.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on A shares. Citigroup increased their target price on shares of Agilent Technologies from $185.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday. Piper Sandler began coverage on Agilent Technologies in a research report on Thursday, June 11th. They issued a “neutral” rating and a $150.00 price target on the stock. Stifel Nicolaus upped their price objective on Agilent Technologies from $170.00 to $180.00 and gave the company a “buy” rating in a research note on Thursday. HSBC decreased their price objective on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Finally, Bank of America lifted their target price on Agilent Technologies from $155.00 to $180.00 and gave the company a “buy” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $170.33.

More Agilent Technologies News

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent exceeded quarterly expectations. Fiscal Q3 revenue rose 8.1% year over year to $1.88 billion, above the $1.84 billion consensus estimate. Non-GAAP EPS was $1.62, ahead of the $1.49 estimate and up from $1.37 a year earlier. GAAP net income reached $362 million, or $1.28 per share. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: Management raised its fiscal 2026 outlook. Full-year adjusted EPS guidance increased to $6.18-$6.21, above the $6.06 analyst consensus, while revenue guidance of approximately $7.5 billion also exceeded expectations. Fourth-quarter EPS guidance of $1.71-$1.74 was at or above consensus. Agilent raises annual profit forecast on improving lab tools demand
• Positive Sentiment: Growth and operating leverage are improving. Operating profit rose 23.3% to $444 million, while operating cash flow increased 43.4% to $519 million. Commentary highlighted product momentum, recovering Chinese demand and margin expansion as drivers of the stronger performance. A Q2 Deep Dive: Product Momentum, China Recovery, and Operating Leverage Drive Results
• Positive Sentiment: Analyst sentiment strengthened materially. Citigroup, JPMorgan, RBC, Stifel, Bank of America, Goldman Sachs, Barclays, TD Cowen and Bernstein all raised price targets, with new targets generally ranging from $175 to $190 and buy, overweight or outperform ratings. Analyst price-target updates
• Neutral Sentiment: At roughly 31 times earnings and near its 52-week high, Agilent’s valuation already reflects considerable optimism. Sustaining the rally will likely depend on continued demand recovery and delivery of the raised guidance.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.